Antibe Therapeutics Inc.
 |
|
| Publicly traded corporation | |
| Traded as |
TSX-V: ATE OTCQX: |
| Industry | Pharmaceuticals |
| Headquarters | Toronto, Canada |
|
Key people
|
Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Science Officer |
| Website | www |
Antibe Therapeutics is a Toronto-based pharmaceutical company that develops inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. In 2015, Antibe acquired Citagenix, a developer and distributor involved in regenerative medicine.
The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body. Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation. Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to rheumatoid arthritis and other diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.
In May 2014, the company announced that it had completed pre-clinical studies on ATB-346. In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials. In mid-January 2015, the company announced that clinical trials for its first drug were being suspended due to safety concerns; clinical trials were restarted in March 2015.
Antibe's products have not yet been approved by the US Food and Drug Administration.
Antibe's science advisory board:
Antibe’s board of directors:
...
Wikipedia